EPO and myocardial infarction: Besides, epicardial erythropoietin treatment enhanced FOS and Fzd7 expression and therefore, increased cardiac repaired critical indicators expressions, such as SDF-1, CXCR4, CD34, Bcl-2, cyclin D1, and MMP2, which elevated intracardiac mesenchymal proliferation during early MI period (52).